Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone

Microbial Drug Resistance

Volumn 20, Issue 1, 2014, Pages 39-44

  Lee, Shinwon ^a   Song, Do Young ^a   Cho, Seung Hyun ^b   Kwon, Ki Tae ^a  

^a Daegu Fatima Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIURIA; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SECONDARY CARE CENTER; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CASE-CONTROL STUDIES; CEFTRIAXONE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENE EXPRESSION; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PYELONEPHRITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84893816030     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2013.0075     Document Type: Article

References (31)

1. Bazaz, R., A.L. Chapman, and T.G. Winstanley. 2010. Er-tapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J. Antimicrob. Chemother. 65:1510-1513.
2. Charlson, M.E., P. Pompei, K.L. Ales, and C.R. MacKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
3. Collins, V.L., D. Marchaim, J.M. Pogue, J. Moshos, S. Bheemreddy, B. Sunkara, A. Shallal, N. Chugh, S. Eiseler, P. Bhargava, et al. 2012. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents. Chemother. 56:2173-2177.
4. Cosentini, R., C. Folli, M. Cazzaniga, S. Aliberti, F. Piffer, L. Grazioli, G. Milani, M. Pappalettera, M. Arioli, F. Tar-dini, et al. 2009. Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward. Intern. Emerg. Med. 4:241-247.
5. Friedman, N.D., K.S. Kaye, J.E. Stout, S.A. McGarry, S.L. Trivette, J.P. Briggs, W. Lamm, C. Clark, J. MacFarquhar, A.L. Walton, et al. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137:791-797.
6. Gupta, K., T.M. Hooton, K.G. Naber, B. Wullt, R. Colgan, L.G. Miller, G.J. Moran, L.E. Nicolle, R. Raz, A.J. Schaef-fer, et al. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52:e103-e120.
7. Ha, Y.E., C.I. Kang, E.J. Joo, S.Y. Park, S.J. Kang, Y.M. Wi, D.R. Chung, K.R. Peck, N.Y. Lee, and J.H. Song. 2011. Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis. Scand. J. Infect. Dis. 43:587-595.
8. Harbarth, S., O. Rutschmann, P. Sudre, and D. Pittet. 1998. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch. Intern. Med. 158:182-189.
9. Jacoby, G., P. Han, and J. Tran. 1997. Comparative in vitro activities of carbapenem L-749, 345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob. Agents. Chemother. 41:1830-1831.
10. Jeon, J.H., K. Kim, W.D. Han, S.H. Song, K.U. Park, J.E. Rhee, K.H. Song, W.B. Park, E.S. Kim, S.W. Park, et al. 2012. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob. Agents. Chemother. 56:3043-3046.
11. Kang, C.I., S.H. Kim, D.M. Kim, W.B. Park, K.D. Lee, H.B. Kim, M.D. Oh, E.C. Kim, and K.W. Choe. 2004. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25:860-867.
12. Kang, C.I., S.Y. Park, D.R. Chung, K.R. Peck, and J.H. Song. 2012. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumo-niae. J. Infect. 64:533-534.
13. Kim, B., J. Kim, M.R. Seo, S.H. Wie, Y.K. Cho, S.K. Lim, J.S. Lee, K.T. Kwon, H. Lee, H.J. Cheong, et al. 2013. Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 41:603-612.
14. Kim, S.H., K.H. Kim, H.B. Kim, N.J. Kim, E.C. Kim, M.D. Oh, and K.W. Choe. 2008. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob. Agents. Chemother. 52: 192-197.
15. Kim, S.H., Y.W. Kim, and H.J. Lee. 2012. Serious acute pyelonephritis: a predictive score for evaluation of deterioration of treatment based on clinical and radiologic findings using CT. Acta. Radiol. 53:233-238.
16. Kim, Y.K., H. Pai, H.J. Lee, S.E. Park, E.H. Choi, J. Kim, J.H. Kim, and E.C. Kim. 2002. Bloodstream infections by extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob. Agents. Chemother. 46: 1481-1491.
17. Kola, A., O. Maciejewski, D. Sohr, S. Ziesing, and P. Gastmeier. 2007. Clinical impact of infections caused by ESBL-producing E. coli and K. pneumoniae. Scand. J. Infect. Dis. 39:975-982.
18. Menashe, G., A. Borer, P. Yagupsky, N. Peled, J. Gilad, D. Fraser, K. Riesenberg, and F. Schlaeffer. 2001. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand. J. Infect. Dis. 33:188-193.
19. Meyer, K.S., C. Urban, J.A. Eagan, B.J. Berger, and J.J. Rahal. 1993. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann. Intern. Med. 119:353-358.
20. Naumovski, L., J.P. Quinn, D. Miyashiro, M. Patel, K. Bush, S.B. Singer, D. Graves, T. Palzkill, and A.M. Arvin. 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob. Agents. Chemother. 36:1991-1996.
21. Pai, H. 2011. Treatment of community-acquired uncomplicated urinary tract infection. Korean J. Med. 81:685-689.
22. Paterson, D.L., and R.A. Bonomo. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
23. Pitout, J.D., and K.B. Laupland. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166.
24. Pitout, J.D., P. Nordmann, K.B. Laupland, and L. Poirel. 2005. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J. An-timicrob. Chemother. 56:52-59.
25. Rodriguez-Bano, J., J.C. Alcala, J.M. Cisneros, F. Grill, A. Oliver, J.P. Horcajada, T. Tortola, B. Mirelis, G. Navarro, M. Cuenca, et al. 2008. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 168:1897-1902.
26. Rodriguez-Bano, J., M.D. Navarro, P. Retamar, E. Picon, and A. Pascual. 2012. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin. Infect. Dis. 54:167-174.
27. Rodriguez-Bano, J., and A. Pascual. 2008. Clinical significance of extended-spectrum beta-lactamases. Expert Rev. Anti. Infect. Ther. 6:671-683.
28. Rodriguez-Bano, J., E. Picon, P. Gijon, J.R. Hernandez, M. Ruiz, C. Pena, M. Almela, B. Almirante, F. Grill, J. Colomina, et al. 2010. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis. 50:40-48.
29. Schwaber, M.J., S. Navon-Venezia, K.S. Kaye, R. BenAmi, D. Schwartz, and Y. Carmeli. 2006. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents. Chemother. 50:1257-1262.
30. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, The Korean Society of Clinical Microbiology. 2011. Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis. Infect. Che-mother. 43:1-25.
31. Tumbarello, M., T. Spanu, M. Sanguinetti, R. Citton, E. Montuori, F. Leone, G. Fadda, and R. Cauda. 2006. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents. Chemother. 50:498-504.